News

News

                        Array
(
    [0] => stdClass Object
        (
            [id] => 1341
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 2-1752034596.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-07-12
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-07-12 10:15:24
            [updated_time] => 2025-07-24 13:42:33
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Diagnosis-and-treatment-of-genetic-diseases-advances-and-new-solutions-
            [title] => Diagnosis and Treatment of Genetic Diseases: Advances and New Solutions
            [description] => The diagnosis and treatment of genetic diseases have become one of the most rapidly advancing fields in medicine, bringing new hope to millions of patients around the world. With the development of technology, from early diagnostic techniques to optimized treatment methods, the detection and management of genetic disorders have become more accurate and effective than ever. These groundbreaking solutions not only improve patients' quality of life but also lay a solid foundation for the future.
            [content] => 

Detecting Balanced Translocations in Preimplantation Embryos Using PGT Technology

Ths. Nguyễn Văn Huynh (Chuyên viên GENTIS) trình bày những ưu điểm của xét nghiệm PGT-UPGRADE

MSc. Nguyen Van Huynh (GENTIS Specialist) presented the advantages of PGT-UPGRADE testing.

The detection and analysis of balanced translocations in preimplantation embryos are opening a new chapter in the search for "healthy seeds of life" for couples undergoing infertility treatment. This advanced technique enables the screening of potential genetic abnormalities from the earliest stages of embryonic development, allowing for precise selection of the best embryos for uterine transfer.

One of the most notable breakthroughs today is PGT-UPGRADE—a deep genetic analysis method developed by GENTIS using international-standard Next-Generation Sequencing (NGS) technology. In addition to comprehensively detecting aneuploidy across all 24 chromosomes, PGT-UPGRADE is specialized in identifying genetic balanced translocations—a factor that conventional tests often miss but may be the root cause of recurrent miscarriages, IVF failure, or congenital abnormalities.

In clinical practice, PGT-UPGRADE helps screen and select embryos that do not carry the same balanced translocation as either parent, thereby minimizing the risk of passing genetic abnormalities to the next generation and eliminating reproductive complications caused by such translocations. It is the optimal solution for couples with balanced translocations—allowing proactive selection of genetically normal embryos, increasing IVF success rates, reducing pregnancy risks, and offering the chance of welcoming a healthy baby.

Zygote Formation Abnormalities in IVF and Detection Methods

TS. BS. Bùi Thị Phương Hoa (Trưởng phòng nghiên cứu khoa học và đào tạo - Bệnh viện Nam học và Hiếm muộn Hà Nội) trình bày về các bất thường trong quá trình thụ tinh trong ống nghiệm và phương pháp phát hiện

Dr. Bui Thi Phuong Hoa (Head of Research and Training Department – Hanoi Hospital of Andrology and Infertility) presented on abnormalities during in vitro fertilization and their detection.

In IVF procedures, abnormalities in zygote formation are one of the main causes of implantation failure and unsuccessful pregnancies. These may include chromosomal number anomalies or genetic mutations that lead to severe disorders.

Today, the detection of such abnormalities relies heavily on advanced genetic testing technologies such as chromosomal analysis using NGS or CGH array methods. These tests allow early detection of abnormalities that might affect IVF success, enabling physicians to make appropriate decisions in selecting healthy embryos for transfer.

With support from these modern detection methods, IVF failure rates have significantly decreased. This not only helps families save time and costs but also minimizes the risk of passing hereditary diseases to their children. The increasing accuracy of these methods is building strong trust among couples on their journey to parenthood.

Developing Interpretation Software for Newborn Screening Using LC-MS/MS

Ths. BSNT Đinh Thị Quỳnh Ngọc (Chuyên viên GENTIS) báo cáo về quá trình phát triển phần mềm phiên giải kết quả cho xét nghiệm SLSS bằng phương pháp LC - MS/MS

MSc., Resident Doctor Dinh Thi Quynh Ngoc (GENTIS Specialist) reported on the development of interpretation software for newborn screening results using the LC-MS/MS method.

Newborn screening is one of the key measures for early detection of genetic and congenital metabolic disorders that can seriously affect the health and development of infants. Among screening techniques, Tandem Mass Spectrometry (UPLC-MS/MS) is increasingly becoming a modern method for accurately identifying abnormalities from birth. However, one of the current major challenges is result interpretation—which requires a combination of high precision and rapid processing speed.

To meet this need, the development of interpretation software for newborn screening using mass spectrometry has emerged as a breakthrough in enhancing healthcare service quality. These software solutions automate the entire data analysis process and assist doctors in making timely and accurate clinical decisions—from monitoring to treatment.

In particular, leading institutions in genetics in Vietnam, such as GENTIS, are investing in building advanced interpretation systems that optimize analysis performance and reduce errors during result reading. The participation of experienced units like GENTIS not only enhances the reliability of screening systems but also promotes the application of high technology in precision medicine in Vietnam.

GENTIS – A Trusted Partner in the Diagnosis and Treatment of Genetic Disorders

GENTIS has established itself as a pioneer in genetic technology research and application, providing accurate testing services along with diagnostic and treatment support software. With advanced technologies and a team of experienced experts, GENTIS remains a reliable partner for hospitals, clinics, and genetic research centers. In addition to developing technical solutions, GENTIS also offers consultation to support physicians and families throughout the treatment process.

Thanks to continuous technological advances, methods such as PGT, newborn screening using mass spectrometry, and result interpretation software are transforming how genetic diseases are diagnosed and treated. As a leader in genetic testing, GENTIS not only improves healthcare quality but also helps reduce the prevalence of preventable genetic conditions.

[content_more] => [meta_title] => Diagnosis and Treatment of Genetic Diseases: Advances and New Solutions [meta_description] => The diagnosis and treatment of genetic diseases have become one of the most rapidly advancing fields in medicine, bringing new hope to millions of patients around the world. [meta_keyword] => GENTIS,genetic [thumbnail_alt] => [post_id] => 1341 [category_id] => 4 ) [1] => stdClass Object ( [id] => 1340 [id_crawler] => [category_product] => NULL [thumbnail] => nht05500.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2025-07-12 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2025-07-12 09:52:47 [updated_time] => 2025-07-24 13:35:15 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => GENTIS-accompanies-the-annual-scientific-conference-of-Phuong-Chau-healthcare-group-2025 [title] => GENTIS Accompanies the Annual Scientific Conference of Phuong Chau Healthcare Group 2025 [description] => On July 11, 2025, the Annual Scientific Conference of Phuong Chau Healthcare Group (ACP 2025) was successfully held in Can Tho City, attracting over 800 delegates, experts, and guests. With the theme “JCI & JCI Enterprise – The Symphony of Healthcare Operations,” this year’s event once again affirmed ACP’s reputation as one of the leading specialized medical scientific conferences in Vietnam. The conference serves as a platform connecting scientists, doctors, and healthcare professionals, while also updating attendees on medical advancements across various fields to improve healthcare service quality in the region. [content] =>

As a supporting sponsor, GENTIS was honored to participate in the conference and received much attention and appreciation from the professional community. This was an opportunity for GENTIS to reaffirm its role in the fields of genetic analysis and precision medicine—key components in the modern healthcare ecosystem.

JCI – A Global Benchmark for Healthcare Quality

The theme “JCI & JCI Enterprise – The Symphony of Healthcare Operations” was not only a highlight of ACP 2025 but also a testament to Phuong Chau Healthcare Group’s journey in enhancing healthcare quality. JCI (Joint Commission International) is one of the world’s most rigorous standards for healthcare quality and safety, with over 2,500 stringent criteria, including patient safety, infection control, medication management, emergency response, quality management, and safety for healthcare workers.

Phuong Chau Healthcare Group is proud to be among the top 10 healthcare groups globally and the first in Southeast Asia to be accredited with JCI Enterprise. Additionally, 3 out of 4 hospitals in its network have achieved JCI accreditation: Phuong Chau Can Tho, Phuong Chau Soc Trang, and Phuong Nam. This milestone is not only a source of pride for Phuong Chau but also marks a significant step forward for Vietnam’s healthcare sector on the global stage.

ACP 2025 – Gathering Leading Domestic and International Experts

ACP 2025 brought together many of Vietnam’s top JCI-accredited hospitals, including Vinmec Central Park, FV Hospital, American International Hospital (AIH), Cao Thang Eye Hospital, and of course, the host—Phuong Chau Healthcare Group. The conference also featured international experts from The Medical City (Philippines)—a renowned ASEAN hospital with JCI accreditation—alongside leading specialists in Obstetrics, Gynecology, and Neonatology.

The conference was structured into 10 thematic sessions, with 36 in-depth presentations covering key topics such as:

  • High-quality operational models and holistic employee care
  • Safety in treatment
  • Safety in laboratory and diagnostic services
  • Safety in IT and healthcare infrastructure
  • In-depth updates and notable clinical cases in Obstetrics, Gynecology, and Neonatology

The diversity and depth of the sessions reflect the medical community’s ongoing commitment to advancing knowledge, improving clinical practice, and adopting modern healthcare management models.

GENTIS – A Pioneer in Genetic Analysis, Partnering with Modern Medicine

As a pioneering institution in genetic testing and precision medicine, GENTIS brought groundbreaking solutions to ACP 2025 that support screening, diagnosis, and personalized treatment. The GENTIS booth at the event attracted special interest from hundreds of delegates and experts. Here, GENTIS showcased cutting-edge technologies already widely applied in leading IVF centers and hospitals:

  • PGT Next: Detects aneuploidy/monosomy in embryos – enhancing success rates in assisted reproduction.
  • PGT Upgrade: Identifies embryos carrying balanced translocations – reducing inherited disease risks.
  • PGT-M for 100+ rare diseases: Screens for over 100 monogenic diseases – helping carrier couples select healthy embryos.
  • PGT MAX 1: High-resolution genetic screening – increasing screening accuracy.
  • Thrombophilia: Screens for gene mutations associated with clotting disorders – particularly important during pregnancy.
  • Thalassemia: Screens for inherited anemia – minimizing the risk of having a child with thalassemia.
  • Genratest: Determines the optimal implantation window – maximizing IVF treatment success.

Through these innovative products and services, GENTIS continues to bridge the gap between scientific research and practical application, contributing significantly to improving treatment outcomes and quality of life.

Commitment to a Sustainable Healthcare Mission

ACP 2025 stands as a clear testament to the effective collaboration between healthcare organizations, experts, scientists, and businesses. GENTIS is proud to accompany the conference in its mission to spread knowledge, foster professional connections, and build a healthcare system that is high-quality, safe, and patient-centered.

Looking ahead, GENTIS hopes to continue its partnership with ACP and both domestic and international partners to fulfill its mission: “Enhancing the intellect and physical well-being of Vietnamese people” through advanced, accurate, and personalized genetic testing solutions.



[content_more] => [meta_title] => GENTIS Accompanies the Annual Scientific Conference of Phuong Chau Healthcare Group 2025 [meta_description] => On July 11, 2025, the Annual Scientific Conference of Phuong Chau Healthcare Group (ACP 2025) was successfully held in Can Tho City, attracting over 800 delegates, experts, and guests [meta_keyword] => GENTIS [thumbnail_alt] => [post_id] => 1340 [category_id] => 4 ) [2] => stdClass Object ( [id] => 1339 [id_crawler] => [category_product] => NULL [thumbnail] => mit-tinh-dan-so-1175555-17522056073271904440640.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 1 [displayed_time] => 2025-07-11 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2025-07-11 14:49:39 [updated_time] => 2025-07-24 10:44:21 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Gentis-joins-the-general-office-for-population-ministry-of-health-in-the-rally-celebrating-world-population-day-2025-shaping-population-policies-for-human-rights-and-sustainable-developement [title] => GENTIS Joins the General Office for Population – Ministry of Health in the Rally Celebrating World Population Day 2025: Shaping Population Policies for Human Rights and Sustainable Development [description] => On the morning of July 11, 2025, in Hanoi, the General Office for Population – Ministry of Health, in collaboration with the United Nations Population Fund (UNFPA) in Vietnam, held a grand rally in response to World Population Day with the theme: "Reproductive Autonomy in a Changing World." The event attracted participation from central and local government agencies, healthcare organizations, international organizations, and notably, the presence of GENTIS – Genetic Testing Services JSC, a pioneering company in the field of genetic testing in Vietnam. [content] =>

Raising Awareness and Promoting Reproductive Autonomy

World Population Day (July 11) is an opportunity for the international community to reflect on the challenges and opportunities in population and development. This year’s theme, "Reproductive Autonomy in a Changing World," emphasizes the importance of individual rights—particularly for women—in making decisions about reproductive health and family planning.

In her speech at the rally, Minister of Health Dao Hong Lan stressed:

“The revised Population Ordinance of 2025 has just been passed. It recognizes and respects the reproductive autonomy of individuals and couples—decisions made voluntarily and in accordance with their health conditions and circumstances. This spirit aligns perfectly with the message of this year's World Population Day.”

GENTIS representative together with MSc. Dr. Mai Trung Son – representative of the General Office for Population, Ministry of Health

In the face of demographic shifts, rapid urbanization, climate change, population aging, and persistent gender inequality, empowering individuals with reproductive decision-making has become more crucial than ever. It is not only a matter of human rights but also a key to achieving sustainable development goals.

GENTIS – Supporting Reproductive Health and Genetic Quality

At the event, MSc. Dr. Mai Trung Son, representative of the General Office for Population – Ministry of Health, commended GENTIS for its contributions to reproductive healthcare and improving population quality. He praised GENTIS’s strong sense of social responsibility and its active participation in the rally. The company’s involvement underscores the growing role of medical technology enterprises in supporting national population goals.

As a leader in the field of genetic testing, GENTIS has been making significant contributions to reproductive health and population quality improvement in Vietnam. By joining this important event alongside the Ministry of Health, GENTIS not only demonstrates its social commitment but also delivers a powerful message about the role of science and technology in protecting and promoting reproductive rights.

During the rally, GENTIS offered small gifts along with informational materials on solutions to help couples have healthy children—such as non-invasive prenatal testing (NIPT) and genetic testing in assisted reproduction. Through these services, GENTIS helps realize the right to access scientific information and the right to choose safe, healthy childbirth options—perfectly in line with the theme of World Population Day 2025.

In a society increasingly focused on genetic health and the well-being of future generations, GENTIS's genetic solutions are becoming essential tools for supporting Vietnam’s population policies. The World Population Day 2025 rally serves as a reminder of our collective responsibility. As a leading provider in reproductive support, GENTIS reaffirms its commitment to working alongside healthcare agencies and communities to protect reproductive rights, for a healthy and sustainable future for all generations of Vietnamese people.

[content_more] => [meta_title] => GENTIS Joins the General Office for Population – Ministry of Health in the Rally Celebrating World P [meta_description] => On the morning of July 11, 2025, in Hanoi, the General Office for Population – Ministry of Health, in collaboration with the United Nations Population Fund (UNFPA) in Vietnam, held a grand rally in response to World Population Day with the theme: "Reprodu [meta_keyword] => GENTIS [thumbnail_alt] => [post_id] => 1339 [category_id] => 4 ) [3] => stdClass Object ( [id] => 1338 [id_crawler] => [category_product] => NULL [thumbnail] => tin-tuc/the_best_2025/rabbit-1438.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2025-07-11 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2025-07-11 13:44:26 [updated_time] => 2025-07-21 15:00:06 [files] => [salary] => [time] => [created_by] => 1 [is_table_content] => 0 [language_code] => en [slug] => gentis-lot-top-10-lab-di-truyen-tot-nhat-viet-nam-tai-le-trao-giai-the-best-of-vietnam-2025 [title] => GENTIS Named One of Vietnam’s Top 10 Genetic Laboratories at The Best of Vietnam 2025 Awards [description] => On July 5, 2025, at The Best of Vietnam 2025 awards ceremony, Genetic Analysis Services Joint Stock Company (GENTIS) was honored to receive the prestigious award recognizing it as one of the Top 10 Genetic Laboratories in Vietnam. This recognition is a well-deserved testament to GENTIS’s persistent efforts, innovation, and pioneering spirit in advancing the field of genetics in Vietnam. [content] =>

A Milestone Affirming Its Pioneering Role

The Best of Vietnam is a prestigious annual awards program that celebrates brands and enterprises with outstanding achievements and positive contributions to Vietnam’s economic, social, and technological development. This year’s program was co-organized by Intellectual Property and Innovation Magazine, the Vietnam Union of Science and Business, the Vietnam Institute for Standard Compliance and Quality, and various other reputable organizations.

To be honored, companies must pass a rigorous evaluation system based on international standards, including technological capabilities, quality management systems, expert teams, brand reputation, social contributions, and customer feedback.

Among all institutions in the field of genetic testing and analysis across the country, GENTIS stood out and was selected as one of Vietnam’s Top 10 Genetic Laboratories, thanks to its internationally standardized laboratories, advanced testing technologies, and a nationwide service network.

GENTIS proudly receives the Top 10 Genetic Laboratory award at The Best of Vietnam 2025 ceremony.

A Journey of Constant Innovation and Technological Investment

Founded in 2010, GENTIS was one of the first companies to bring genetic testing services closer to Vietnamese people. Starting with paternity testing, GENTIS has continuously expanded and invested in advanced services such as non-invasive prenatal testing (NIPT), preimplantation genetic testing (PGT), and genetic screening for hereditary diseases.

With a long-term strategic vision, GENTIS consistently invests in research and development, upgrades equipment, and applies cutting-edge technologies such as Next Generation Sequencing (NGS), Microarray, and Real-time PCR, ensuring the highest level of accuracy for every test.

All of GENTIS’s analyses are conducted in laboratories certified to CAP, ISO 15189:2022, and ISO/IEC 27001:2022 standards, strictly monitored according to international quality procedures. The team of specialists and technicians at GENTIS are not only highly qualified but also receive ongoing training from international partners and top medical universities both in Vietnam and abroad.

Mr. Bùi Quốc Kha – Deputy Director of GENTIS Ho Chi Minh City Branch – receives the Top 10 Genetic Laboratory Award.

GENTIS – A Trusted Brand

Beyond its focus on technology, GENTIS places great emphasis on customer experience and in-depth consultation services. Every client is guided by a professional team, with absolute confidentiality of personal information, and results are interpreted by top genetics experts.

GENTIS is currently a strategic partner of hundreds of hospitals, fertility centers, and clinics across the country. It also collaborates with various international institutions in genetic research and disease screening.

As of 2025, GENTIS has served millions of customers, many of whom have successfully applied genetic analysis results for early detection and timely intervention of genetic disorders—contributing to improved quality of life and reduced medical burden on society.

Furthermore, GENTIS actively engages in community programs, including free genetic testing, public seminars on genetics, and collaborative research with hospitals. These initiatives reflect GENTIS’s strong commitment to enhancing public health—especially in maternal and child care.

A Strong Commitment to Sustainable Development

Speaking at the award ceremony, Mr. Bùi Quốc Kha, Deputy Director of GENTIS Ho Chi Minh City Branch, said:
“Being named among the Top 10 Genetic Laboratories in Vietnam is a tremendous honor for GENTIS. It not only recognizes our relentless efforts over the past 15 years but also motivates us to continue our pioneering mission in genetic analysis. We are committed to further research, innovation, and investment to deliver optimal, accurate, and timely genetic testing solutions that enhance community health care.”

The event also gathered outstanding businesses from diverse sectors such as healthcare, technology, education, manufacturing, and finance—sharing development visions and affirming the role of Vietnamese enterprises in the era of global integration. At the same time, the program strongly supported the campaign “Vietnamese people prioritize using Vietnamese products”, a key policy encouraged by the Politburo for broad public implementation.

Certificate and trophy awarded to GENTIS as one of the Top 10 Genetic Laboratories in Vietnam.

Elevating Vietnamese Genetic Testing to the Global Stage

GENTIS’s success in Vietnam is just the beginning. The company is gradually expanding its influence regionally and globally through partnerships with international labs, research centers, and hospitals. GENTIS aims not only to offer modern genetic testing services to Vietnamese people but also to put Vietnam on the global map of genetic technology.

In the near future, GENTIS aspires to become a leading tech company in genetic analysis applications, helping make Vietnam a trusted medical destination in the region.


About GENTIS
Genetic Analysis Services Joint Stock Company (GENTIS), founded in 2010, is a pioneer in providing high-quality genetic testing services in Vietnam. With internationally accredited laboratories, modern technology, and a team of reputable experts, GENTIS delivers advanced genetic solutions for personalized, comprehensive health care and disease prevention.

[content_more] => [meta_title] => GENTIS Named One of Vietnam’s Top 10 Genetic Laboratories at The Best of Vietnam 2025 Awards [meta_description] => On July 5, 2025, at The Best of Vietnam 2025 awards ceremony, Genetic Analysis Services Joint Stock Company (GENTIS) was honored to receive the prestigious award recognizing it as one of the Top 10 Genetic Laboratories in Vietnam. [meta_keyword] => [thumbnail_alt] => [post_id] => 1338 [category_id] => 4 ) [4] => stdClass Object ( [id] => 1335 [id_crawler] => [category_product] => NULL [thumbnail] => cac_logo-02.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2025-07-07 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2025-07-07 15:04:01 [updated_time] => 2025-07-25 08:44:37 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Eurofins-GENTIS-a-milestone-in-bringing-Vietnamese-genetic-science-to-the-global-stage [title] => Eurofins GENTIS – A Milestone in Bringing Vietnamese Genetic Science to the Global Stage [description] => From a startup in France, Eurofins has grown into one of the world’s leading scientific groups, particularly in the field of biological testing, including medical testing, with over 900 laboratories worldwide. The integration of GENTIS into the Eurofins network marks a strategic turning point, ushering in a new era for genetic testing in Vietnam and Southeast Asia. [content] =>

Eurofins – A Global Leader in Scientific Services
Eurofins Scientific is a world-leading group specializing in testing, inspection, and certification services for quality management systems across food, consumer products, environment, pharmaceuticals, and genetic analysis. Founded in October 1987 in Nantes, France with just four employees, Eurofins began as a young science-based company. From the very beginning, Eurofins set a clear vision – "Testing for Life" – contributing to scientific progress and protecting public health.

After more than three decades of rapid growth, Eurofins has become one of the largest scientific service providers in the world, with:

  • Over 62,000 employees across more than 900 laboratories globally

  • A leading position in testing for food, pharmaceuticals, cosmetics, agriculture, and a strong presence in advanced fields such as materials science, genomics, forensics, consumer products, and clinical diagnostics

  • Operations in over 62 countries, forming a cross-border scientific network where technological advances are shared, applied, and optimized with a shared mission: To make the world a safer, healthier place to live

This remarkable growth is not only about scale but also embodies the Eurofins spirit – a unique identity in the scientific community characterized by continuous innovation, investment in technology, service quality enhancement, and most importantly, a commitment to building a safer, healthier world. Eurofins affirms its leadership in innovation, accuracy, and quality in life sciences – continually setting global trends and standards. It is home to some of the brightest minds, always at the forefront of research, technological applications, and global standard development.

GENTIS – A Vietnamese Mark in the Global Eurofins Network
In February 2022, GENTIS officially joined the global Eurofins family – a historic milestone for life sciences in Vietnam, as a pioneer in genetic analysis became part of one of the world’s leading healthcare groups.

The integration of GENTIS into Eurofins is not merely an expansion in scale but a strategic connection between a powerful international corporation and a Vietnamese pioneer in genetic testing.

As a trailblazer in Vietnam specializing in genetic and DNA testing, GENTIS has established a leading position with millions of trusted customers, a team of experts, and laboratories that meet international standards.

The transformation of Eurofins GENTIS into a foreign-invested company carries profound strategic significance:

  • Access to world-leading technologies, improving testing capacity and service quality

  • Participation in a global scientific research network, expanding professional collaboration and sharing international knowledge

  • Bringing high-quality genetic testing services closer to the Vietnamese population, contributing to better public healthcare

At the same time, GENTIS will become a strategic hub for Eurofins in Southeast Asia, contributing to the group's ambition to expand genetic testing services in this highly potential region.

Eurofins GENTIS – Strong Leadership, Forward to the Future
Eurofins GENTIS represents the synergy of global strength and local expertise – combining international stature with deep local understanding. This perfect integration aims to bring advanced genetic testing services to millions of people in Vietnam and the region.

With Eurofins' global technology, team, and network, along with a solid scientific foundation, Eurofins GENTIS officially enters a new stage of development – becoming a pioneer in genetic analysis, leading Vietnam, and aiming to lead Southeast Asia.

[content_more] => [meta_title] => Eurofins GENTIS – A Milestone in Bringing Vietnamese Genetic Science to the Global Stage [meta_description] => From a startup in France, Eurofins has grown into one of the world’s leading scientific groups, particularly in the field of biological testing, including medical testing, with over 900 laboratories worldwide. [meta_keyword] => GENTIS,Eurofins [thumbnail_alt] => [post_id] => 1335 [category_id] => 4 ) [5] => stdClass Object ( [id] => 1334 [id_crawler] => [category_product] => NULL [thumbnail] => f1faa4a7ec1c5b42020d.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2025-07-03 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2025-07-03 10:14:20 [updated_time] => 2025-07-25 08:53:35 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Gentis-to-present-oral-report-at-ESHRE-2025-with-Research-on-segmental-mosaic-embryo-transfer [title] => GENTIS to Present Oral Report at ESHRE 2025 with Research on Segmental Mosaic Embryo Transfer [description] => A scientific study conducted by GENTIS, in collaboration with experts from Genoma and several other institutions in Vietnam and around the world, has been selected for an oral presentation at the ESHRE 2025 conference. [content] =>

ESHRE – The World’s Leading Annual Event in Reproductive Medicine
ESHRE (European Society of Human Reproduction and Embryology) is the largest international conference in the field of reproductive medicine and embryology. Held annually in July by the European Society of Human Reproduction and Embryology, the event brings together thousands of experts, researchers, physicians, and global health organizations to share knowledge, research findings, and the latest trends in the treatment of infertility.

In 2025, the ESHRE conference will take place at the Paris Convention Centre – Porte de Versailles, one of the most modern and largest venues in Europe, from June 29 to July 2, 2025. This is a valuable opportunity for healthcare professionals to update their knowledge, expand professional networks, and jointly advance the field of reproductive medicine – a domain deeply rooted in human compassion and care.

GENTIS Research on Segmental Mosaic Embryos Selected for Oral Presentation

GENTIS is honored to have its research project titled: “Decoding the clinical fate of segmental mosaic embryos: key predictors of implantation and pregnancy success”
(selected Vietnamese title: "Giải mã kết cục lâm sàng chuyển phôi khảm cấu trúc một phần: các yếu tố chủ đạo dự đoán sự thành công chuyển phôi và mang thai IVF")
chosen by the ESHRE Scientific Committee for oral presentation – the highest and most prestigious form of presentation at the conference.

The Study Focuses on Segmental Mosaic Embryos – A Promising Yet Controversial Path in IVF
The research centers on segmental mosaic embryos – a type of embryo containing both normal and abnormal cells due to errors in mitotic cell division. The use of such embryos in IVF has long been controversial, yet it presents a promising option when no euploid embryos (chromosomally normal) are available.

The main objective of the study is to evaluate the implantation potential, pregnancy outcomes, and live birth rates of segmental mosaic embryos, thereby identifying key predictors of clinical success and proposing safer embryo selection criteria for IVF practice.

Data and Research Methods
This is a retrospective study, analyzing data from 3,790 mosaic embryos recorded in the International Registry of Mosaic Embryo Transfers (IRMET) between 2017 and 2024. The methodology includes:

  • Embryo classification:
    • Segmental mosaic embryos: 1,567
    • Whole-chromosome mosaic embryos: 1,723
    • Euploid embryos: 19,258

  • Embryo characteristics:
    • Degree of mosaicism (percentage of abnormal cells)
    • Type of abnormality (segmental deletion or duplication)
    • Size of the affected chromosomal segment
    • Embryo morphology (Inner Cell Mass – ICM, and Trophectoderm – TE)
    • Timing of biopsy (Day 4–6)

  • Clinical outcomes analyzed:
    • Implantation rate
    • Clinical pregnancy rate
    • Live birth rate
    • Miscarriage rate

  • Statistical methods:
    • Logistic regression analysis
    • Chi-square tests
    • Standardized sequencing platform for consistent results

Key Findings
The study revealed several important factors that directly influence the clinical success of mosaic embryo transfer, including:

  • The ongoing pregnancy rate (OPR) for segmental mosaic embryos was 45.5%, higher than whole-chromosome mosaics (34.3%) but lower than euploid embryos (50%).

  • Higher levels of mosaicism significantly reduced OPR:
    • 50% success at 20% mosaicism
    • 45% at 30–40%
    • Only 27% at 60%

  • Embryos with small deletions, particularly on short chromosomal arms, showed higher success rates compared to large deletions or duplications.

  • Timing of biopsy strongly affected outcomes: biopsies done on Day 4–5 yielded better results than those on Days 5 or 6.

  • Embryos with high-quality morphology (ICM and TE) achieved superior clinical outcomes.

These findings emphasize that embryo selection for mosaic transfer should be based on multiple integrated criteria, rather than solely relying on classification from PGT-A (Preimplantation Genetic Testing for Aneuploidy).

Significance and Contributions of the Study
This research represents the first large-scale dataset on segmental mosaic embryos, with contributions from 20 IVF centers worldwide. Its practical impact includes:

  • Enhancing clinical understanding of mosaic embryo behavior

  • Supporting more informed and optimized embryo selection

  • Contributing to the standardization of PGT-A reporting criteria, ultimately improving the safety and effectiveness of mosaic embryo transfer

This study also marks an important milestone for GENTIS, showcasing its commitment to rigorous scientific research, alignment with global trends, and its mission to accompany patients on their journey through infertility treatment.

Being selected for an oral presentation at ESHRE 2025 is a proud achievement, not only for GENTIS but for Vietnam’s entire reproductive medicine community. We firmly believe that our continued efforts in research and innovation will enhance IVF success rates and expand the possibility of parenthood for millions of families around the world.

[content_more] => [meta_title] => GENTIS to Present Oral Report at ESHRE 2025 with Research on Segmental Mosaic Embryo Transfer [meta_description] => A scientific study conducted by GENTIS, in collaboration with experts from Genoma and several other institutions in Vietnam and around the world, has been selected for an oral presentation at the ESHRE 2025 conference. This marks a significant milestone, [meta_keyword] => GENTIS,ESHRE [thumbnail_alt] => [post_id] => 1334 [category_id] => 4 ) [6] => stdClass Object ( [id] => 1333 [id_crawler] => [category_product] => NULL [thumbnail] => b45ce3cee13e56600f2f.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2025-06-28 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2025-06-28 09:57:48 [updated_time] => 2025-07-25 09:08:40 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => GENTIS-joins-the-2025-national-conference-on-medical-genetics-as-an-official-sponsor [title] => GENTIS Joins the 2025 National Conference on Medical Genetics as an Official Sponsor [description] => Continuing its mission to support the medical community in advancing genomic medicine in Vietnam, GENTIS is honored to participate in the 2025 National Conference on Medical Genetics as an official sponsor. This annual, nationwide scientific event brings together leading experts, scientists, physicians, and professionals in the field of genetics. [content] =>

  • Date: July 4–5, 2025

  • Venue: Thanh Hoa Campus – Hanoi Medical University

A Focus on the Latest Advances in Genomic Medicine

This year’s conference highlights cutting-edge advancements in genomic medicine, offering a diverse and in-depth academic program. The sessions and discussions will revolve around five key topics:

  1. Indications and genetic testing before and during pregnancy

  2. Applications of genomic medicine in cancer diagnosis and treatment

  3. Genomic interpretation – from genotype to phenotype

  4. Infertility and assisted reproductive technologies (ART)

  5. Updates on treatment progress for genetic disorders

The conference targets a professional audience, including clinical specialists, physicians, researchers, laboratory technicians, and healthcare professionals working in: clinical genetics, genetic counseling, molecular biology, cell biology, precision medicine, and medical diagnostics.

GENTIS – A Pioneer in Genetic Testing, Advancing Genomic Medicine in Vietnam

At the 2025 National Conference on Medical Genetics, GENTIS will not only showcase its genetic testing solutions applied in clinical practice, but will also contribute academically through valuable scientific presentations delivered by the company’s R&D team.

GENTIS Highlights at the Conference:

  1. Product & Service Exhibition Booth

    • Showcasing modern genetic and genomic testing services for prenatal screening and diagnosis, reproductive health, oncology, and inherited diseases

    • Professional exchanges with doctors and industry experts

    • Interactive minigames with exciting gifts for attendees

  2. Key Scientific Reports by GENTIS

    Oral Presentations:

    • Mr. Nguyen Van Huynh, MSc – Head of R&D, GENTIS:
      "Detection of Balanced Translocations in Preimplantation Embryos Using PGT Technology"

    • Dr. Đinh Thi Quynh Ngoc, MSc, MD – R&D Specialist, GENTIS:
      "Development of Interpretation Software for Newborn Screening Results via LC-based Methodology"

    Poster Presentation:

    • Dr. Vu Thu Hương, MSc, MD & Dr. Pham Dinh Minh – R&D, GENTIS:
      "Application of Expanded Carrier Screening and PGT-M for Thalassemia in Assisted Reproduction Centers in Vietnam – Potential, Limitations, and Guideline-Based Approaches"

Affirming GENTIS’s Leadership in Genetic Testing

Through its participation in the 2025 National Conference on Medical Genetics, GENTIS continues to affirm its pioneering role in the research, development, and application of genetic testing in Vietnam. We are committed to providing modern, accurate, and highly personalized testing solutions that effectively support the screening, diagnosis, and treatment of genetic conditions.

GENTIS warmly invites all physicians and delegates to visit our booth at the conference to share knowledge, experience new technologies, and explore collaborative opportunities in the field of genetics.

[content_more] => [meta_title] => GENTIS Joins the 2025 National Conference on Medical Genetics as an Official Sponsor [meta_description] => Continuing its mission to support the medical community in advancing genomic medicine in Vietnam, GENTIS is honored to participate in the 2025 National Conference on Medical Genetics as an official sponsor. [meta_keyword] => GENTIS [thumbnail_alt] => [post_id] => 1333 [category_id] => 4 ) [7] => stdClass Object ( [id] => 1332 [id_crawler] => [category_product] => NULL [thumbnail] => z6723330422103_a36164bfd599ec7f26bedc31b939276c.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 1 [displayed_time] => 2025-06-24 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2025-06-24 09:38:28 [updated_time] => 2025-07-24 14:40:35 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => cap-certification-the-international-gold-standard-for-laboratory-quality [title] => CAP Certification – The International Gold Standard for Laboratory Quality [description] => n modern medicine, laboratory testing is no longer just a supplementary tool but a critical factor in diagnosing and treating patients. However, a common misconception is that the quality of laboratory tests mainly depends on advanced equipment, test kits, or highly skilled technicians — as many facilities currently promote. [content] =>

In reality, no single factor can guarantee accurate test results without being part of a comprehensive quality management system. Every stage — from sample collection and processing to analysis and reporting — must operate in a synchronized, controlled, and traceable manner. This system is the true foundation that ensures test results are accurate, consistent, and reliable. This is especially crucial in the field of genetic testing, where even the smallest error can lead to serious consequences for the patient, making a tightly managed system an absolute necessity.

True Quality Comes from a Structured and Unified Operational System

Dr. Nguyen Quang Vinh – Director, GENTIS Laboratory Center

Test results are not simply the output of machines or test kits; they are the outcome of a complex, interconnected process — from input sample evaluation and standardized analysis protocols (PCR, sequencing, NGS), to internationally-aligned data interpretation and practical clinical reporting. Every step serves as a quality control checkpoint, and a single mistake can have serious implications for diagnosis and treatment.

Furthermore, laboratory quality is enhanced through the diversity of equipment and the application of advanced technologies that effectively handle the wide range of complexities in modern medicine. Relying on a single technology, test kit, or device is an outdated approach and no longer suitable for building a high-quality testing system.

Establishing a comprehensive quality management system not only minimizes risks but also fosters strong trust among laboratories, physicians, and patients. When processes are tightly controlled, results are accurate, consistent, and traceable — key criteria that physicians rely on for treatment decisions and that give patients confidence in their test outcomes.

CAP – The Gold Standard in Laboratory Quality Management

Dr. Pham Dinh Minh – Director of R&D, GENTIS (Left) with CAP Representative at GENTIS Laboratory

The CAP (College of American Pathologists) certification is recognized globally as the gold standard in clinical laboratory quality. To earn this certification, laboratories must meet stringent requirements and establish a comprehensive quality management system aligned with international standards. This includes participation in regular external quality assessments, expert evaluations, complete data traceability, and continuous quality improvement.

The CAP standard does not assess equipment or personnel in isolation, but evaluates the entire laboratory operation. Everything from standard operating procedures, sample control, technical performance validation, result analysis, to traceability and incident handling — all must meet the highest benchmarks. As a result, a CAP-certified quality system ensures high accuracy, complete transparency, and maximum patient safety.

Another advantage of CAP certification is its support in effectively applying ISO standards in Vietnam by supplementing them with specialized technical requirements. The integration of CAP with ISO 15189 creates a comprehensive framework that enhances both operational efficiency and technical quality. Vietnamese laboratories achieving CAP certification not only meet global standards but also improve practical operations and result accuracy.

“CAP standards bring tangible value to many stakeholders. For doctors, CAP certification is a key factor that ensures confidence in test accuracy, helping them personalize treatment plans, shorten diagnosis time, and reduce retesting — saving time and cost for patients. For customers, testing at a CAP-certified lab means access to a modern, reliable, internationally compatible system — especially beneficial for patients seeking treatment abroad, as results are widely recognized without the need for retesting. High-quality results also reduce errors and enhance peace of mind in healthcare. In addition, partners working with CAP-certified labs like Gentis gain opportunities for sample exchange, data sharing, clinical research, and providing international-standard services, expanding collaboration and development in the medical field,” shared Dr. Pham Dinh Minh (Director of CAP Laboratory, Gentis - Eurofins).

Gentis – Differentiated by CAP-Standard Quality System

Dr. Tar-Choon Aw – Laboratory Director, Changi General Hospital, CAP Expert (Far Right) working with GENTIS experts

In Vietnam, Gentis is one of the pioneers in building a high-quality genetic testing system that meets international standards. Achieving CAP certification is not just a testament to the continuous commitment to quality improvement, but also affirms Gentis’s unique position in applying a globally standardized quality management system for genetic testing in Vietnam.

While many facilities focus their messaging on technology, equipment, test kits, or technician expertise, Gentis understands that true quality comes from a complete quality management system. A systematic and consistent framework is the key to ensuring trustworthy results. Gentis not only invests in modern equipment but also establishes a tightly controlled quality chain — from sample collection and processing to result reporting. All testing data at Gentis is stored, traceable, and controlled according to ISO standards, and strictly complies with CAP certification requirements.

“When doctors receive test results from Gentis, they’re not just getting a number — they’re receiving an internationally certified result backed by a rigorous quality system. This is what fundamentally sets Gentis apart from units that only invest in technology or technician training. Test quality cannot stem from a single factor — it must be the outcome of a cohesive, tightly controlled system,” emphasized Dr. Pham Dinh Minh

With its CAP certification, Gentis affirms its commitment to quality — not merely in words but through concrete action — serving as clear evidence of its sustainable and truly differentiated path in the field of genetic testing in Vietnam.

[content_more] => [meta_title] => CAP Certification – The International Gold Standard for Laboratory Quality [meta_description] => n modern medicine, laboratory testing is no longer just a supplementary tool but a critical factor in diagnosing and treating patients. However, a common misconception is that the quality of laboratory tests mainly depends on advanced equipment, test kits [meta_keyword] => GENTIS,CAP [thumbnail_alt] => [post_id] => 1332 [category_id] => 4 ) )

Diagnosis and Treatment of Genetic Diseases: Advances and New Solutions

The diagnosis and treatment of genetic diseases have become one of the most rapidly advancing fields in medicine, bringing new hope to millions of patients around the world. With the development of technology, from early diagnostic techniques to optimized treatment methods, the detection and management of genetic disorders have become more accurate and effective than ever. These groundbreaking solutions not only improve patients' quality of life but also lay a solid foundation for the future.

GENTIS Accompanies the Annual Scientific Conference of Phuong Chau Healthcare Group 2025

On July 11, 2025, the Annual Scientific Conference of Phuong Chau Healthcare Group (ACP 2025) was successfully held in Can Tho City, attracting over 800 delegates, experts, and guests. With the theme “JCI & JCI Enterprise – The Symphony of Healthcare Operations,” this year’s event once again affirmed ACP’s reputation as one of the leading specialized medical scientific conferences in Vietnam. The conference serves as a platform connecting scientists, doctors, and healthcare professionals, while also updating attendees on medical advancements across various fields to improve healthcare service quality in the region.

GENTIS Joins the General Office for Population – Ministry of Health in the Rally Celebrating World Population Day 2025: Shaping Population Policies for Human Rights and Sustainable Development

On the morning of July 11, 2025, in Hanoi, the General Office for Population – Ministry of Health, in collaboration with the United Nations Population Fund (UNFPA) in Vietnam, held a grand rally in response to World Population Day with the theme: "Reproductive Autonomy in a Changing World." The event attracted participation from central and local government agencies, healthcare organizations, international organizations, and notably, the presence of GENTIS – Genetic Testing Services JSC, a pioneering company in the field of genetic testing in Vietnam.

GENTIS Named One of Vietnam’s Top 10 Genetic Laboratories at The Best of Vietnam 2025 Awards

On July 5, 2025, at The Best of Vietnam 2025 awards ceremony, Genetic Analysis Services Joint Stock Company (GENTIS) was honored to receive the prestigious award recognizing it as one of the Top 10 Genetic Laboratories in Vietnam. This recognition is a well-deserved testament to GENTIS’s persistent efforts, innovation, and pioneering spirit in advancing the field of genetics in Vietnam.

Eurofins GENTIS – A Milestone in Bringing Vietnamese Genetic Science to the Global Stage

From a startup in France, Eurofins has grown into one of the world’s leading scientific groups, particularly in the field of biological testing, including medical testing, with over 900 laboratories worldwide. The integration of GENTIS into the Eurofins network marks a strategic turning point, ushering in a new era for genetic testing in Vietnam and Southeast Asia.

GENTIS to Present Oral Report at ESHRE 2025 with Research on Segmental Mosaic Embryo Transfer

A scientific study conducted by GENTIS, in collaboration with experts from Genoma and several other institutions in Vietnam and around the world, has been selected for an oral presentation at the ESHRE 2025 conference.

GENTIS Joins the 2025 National Conference on Medical Genetics as an Official Sponsor

Continuing its mission to support the medical community in advancing genomic medicine in Vietnam, GENTIS is honored to participate in the 2025 National Conference on Medical Genetics as an official sponsor. This annual, nationwide scientific event brings together leading experts, scientists, physicians, and professionals in the field of genetics.

CAP Certification – The International Gold Standard for Laboratory Quality

n modern medicine, laboratory testing is no longer just a supplementary tool but a critical factor in diagnosing and treating patients. However, a common misconception is that the quality of laboratory tests mainly depends on advanced equipment, test kits, or highly skilled technicians — as many facilities currently promote.
REGISTER FOR SERVICES AT GENTIS
Thank you for choosing and using GENTIS services.
Please fill in the information below to receive our supports and consultations!